Global Preeclampsia Diagnostics Market Revenue Grows at a CAGR of 3.44%

Introduction

Straits Research released its highly anticipated report, “Global Preeclampsia Diagnostics Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 1.08 billion in 2025 and is anticipated to grow to USD 1.46 billion by 2034, growing at a CAGR of 3.44% from 2026-2034.

Market Dynamics

The growth of the preeclampsia diagnostics market is driven by the increasing emphasis on early detection of hypertensive disorders during pregnancy through biomarker-based testing, the rising integration of automated immunoassay platforms in hospital laboratories, and supportive clinical guidelines promoting risk stratification and timely intervention. However, limited accessibility to advanced diagnostic infrastructure in low- and middle-income regions, coupled with the high cost of biomarker assays and lack of awareness among healthcare providers in rural settings, continues to restrain market expansion. On the other hand, growing research into multi-marker predictive panels, the emergence of non-invasive molecular testing, and expanding government initiatives to strengthen prenatal screening programs present significant opportunities for companies to innovate and improve the reach of accurate and affordable preeclampsia diagnostics worldwide.

Market Highlights

• Product Type: The instrument segment is projected to record the fastest growth of 4.64% over the forecast period.
• Test: The urine test segment is anticipated to grow at the fastest CAGR of 4.34%.
• End User: Based on end user, the hospitals segment dominated the market in 2025 with a revenue share of 37.28%.
• Regional Insights: North America dominated the market with more than 11% of market share in 2025.

Competitive Players

1. Abbott
2. Hoffmann-La Roche Ltd
3. Thermo Fisher Scientific Inc. 
4. Revvity Inc.
5. Diabetomics, Inc.
6. QuidelOrtho Corporation
7. Siemens Healthineers AG
8. Bio-Rad Laboratories, Inc.
9. BD
10. Danaher Corporation
11. EKF Diagnostics Holdings plc
12. Sera
13. NX Prenatal Inc. 
14. Metabolomic Diagnostics
15. Akonni Biosystems, Inc.
16. Mirvie, Inc. 
17. Trinity Biotech plc
18. Others

Recent Developments

October 2025: Mirvie, Inc. reported clinical results for its novel, non-invasive blood test designed to assess a woman’s risk of developing preeclampsia during pregnancy. The test evaluated molecular signatures in maternal blood to detect early risk factors prior to the onset of symptoms, enabling clinicians to implement preventive interventions and personalized monitoring strategies. This advancement highlighted the growing application of precision diagnostics in maternal health, emphasizing a shift toward proactive and predictive prenatal care models for preeclampsia management.

Segmentation

1. By Product Type (2026-2034)
   1. Instrument
   2. Consumables
2. By Test (2026-2034)
   1. Blood Test
   2. Urine Test
3. By End-User (2026-2034)
   1. Hospitals
   2. Specialty Clinics
   3. Diagnostic Centers
   4. Others